INTERVENTIONS FOR VALVULAR DISEASE AND HEART FAILURE
Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients
EuroIntervention 2017;13:788-795 published online May 2017. DOI: 10.4244/EIJ-D-16-01024
Ian T. Meredith1*, AM, MBBS, PhD; Nicolas Dumonteil2, MD; Daniel J. Blackman3, MD; Didier Tchétché4, MD; Darren L. Walters5, MBBS; David Hildick-Smith6, MD; Ganesh Manoharan7, MD; Jan Harnek8, MD, PhD; Stephen G. Worthley9, MD, PhD; Gilles Rioufol10, MD, PhD; Thierry Lefèvre11, MD; Thomas Modine12, MD; Nicolas M. Van Mieghem13, MD, PhD; Ted Feldman14, MD; Dominic J. Allocco15, MD; Keith D. Dawkins15, MD; for the REPRISE II Investigators
1. Monash Heart, Monash Medical Centre, and Monash University, Clayton, Victoria, Australia; 2. Clinique Pasteur, Toulouse, France; 3. The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; 4. Clinique Pasteur, Toulouse, France; 5. The Prince Char
Aims: The REPRISE IIE trial aimed to evaluate outcomes following transcatheter aortic valve implantation of the fully repositionable and retrievable LOTUS valve with a unique seal designe
